(BLC) Bastide Le Confort Médical - Ratings and Ratios

Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0000035370

BLC: Medical Equipment, Wellness Accessories, Incontinence Products

Bastide Le Confort Médical SA operates as a specialized distributor of medical and wellness products, catering to both individual consumers and healthcare professionals. The company offers a comprehensive range of medical equipment and supplies, including mobility aids such as manual and electric wheelchairs, walkers, rollators, and electric scooters for individuals with reduced mobility. Additionally, it provides incontinence products, such as absorbent briefs, disposable pads, and hygiene solutions, addressing the specific needs of elderly and healthcare-dependent populations. Its product portfolio also extends to wellness accessories, such as circulatory stimulators, massage gels, and essential oils, reflecting a holistic approach to health and comfort.

The company’s rental services include medical beds, wheelchairs, air mattresses, patient lifts, and verticalizers, providing flexible solutions for short-term or post-acute care needs. Bastide Le Confort Médical SA also serves healthcare professionals with a range of consumables, hygiene products, and diagnostic tools, positioning itself as a one-stop supplier for both clinical and home care settings. Founded in 1977 and headquartered in Caissargues, France, the company has established a strong presence in the European healthcare market, with operations extending beyond France to international territories.

Based on the provided and , the 3-month forecast for Bastide Le Confort Médical SA (Ticker: BLC) can be outlined as follows:

Technical Outlook: - The stock is currently trading at 26.10, above its 20-day (24.28) and 50-day (23.41) moving averages, indicating a bullish short-term trend. - The 200-day moving average (21.18) is significantly lower, suggesting sustained upward momentum over the past year. - Average trading volume (6,685 shares over 20 days) and a low ATR (0.62) signal relatively stable price action, with limited near-term volatility expected.

Fundamental Outlook: - With a market capitalization of 193.67M EUR and a P/E ratio of 28.49, the stock is priced at a premium, reflecting market expectations for future growth. - The P/B ratio of 2.45 indicates that the company is valued above its book value, suggesting investor confidence in its intangible assets and growth prospects. - The P/S ratio of 0.37 points to modest revenue multiples, while an RoE of 7.79% highlights moderate profitability relative to equity.

3-Month Forecast: - : The stock is likely to maintain its upward trajectory, with potential resistance near the SMA 50 level (23.41). Support is expected at the SMA 200 level (21.18). - : Continued demand for healthcare products, particularly in the aging population, is expected to drive revenue growth. However, the high P/E ratio suggests that investor sentiment may be sensitive to earnings performance.

Additional Sources for BLC Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

BLC Stock Overview

Market Cap in USD 193m
Sector Healthcare
Industry Medical Distribution
GiC Sub-Industry Health Care Distributors
IPO / Inception

BLC Stock Ratings

Growth 5y -16.3%
Fundamental 21.4%
Dividend 7.03%
Rel. Strength Industry 36.3
Analysts -
Fair Price Momentum 23.26 EUR
Fair Price DCF 128.45 EUR

BLC Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y -100.00%
Payout Consistency 65.1%

BLC Growth Ratios

Growth Correlation 3m 33.9%
Growth Correlation 12m 60.7%
Growth Correlation 5y -83.1%
CAGR 5y -1.48%
CAGR/Max DD 5y -0.02
Sharpe Ratio 12m -0.10
Alpha 41.04
Beta 0.26
Volatility 36.00%
Current Volume 7.9k
Average Volume 20d 5.7k
What is the price of BLC stocks?
As of March 17, 2025, the stock is trading at EUR 24.30 with a total of 7,910 shares traded.
Over the past week, the price has changed by -1.82%, over one month by -1.62%, over three months by +0.62% and over the past year by +38.07%.
Is Bastide Le Confort Médical a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Bastide Le Confort Médical is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 21.41 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BLC as of March 2025 is 23.26. This means that BLC is currently overvalued and has a potential downside of -4.28%.
Is BLC a buy, sell or hold?
Bastide Le Confort Médical has no consensus analysts rating.
What are the forecast for BLC stock price target?
According to ValueRays Forecast Model, BLC Bastide Le Confort Médical will be worth about 25.1 in March 2026. The stock is currently trading at 24.30. This means that the stock has a potential upside of +3.37%.
Issuer Forecast Upside
Wallstreet Target Price 32.7 34.4%
Analysts Target Price - -
ValueRay Target Price 25.1 3.4%